HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

177Lu-DOTA-octreotate

an somatostatin receptor agonist

Networked: 4 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - Octreotide: 5228
      - 177Lu-DOTA-octreotate: 4
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - Octreotide: 5228
      - 177Lu-DOTA-octreotate: 4
Inorganic Chemicals: 9
- Coordination Complexes: 576
  - 177Lu-DOTA-octreotate: 4
Organic Chemicals: 133
- Coordination Complexes: 576
  - 177Lu-DOTA-octreotate: 4

Experts

1.	Adant, Samuel: 1 article (01/2021)
2.	Beauregard, Jean-Mathieu: 1 article (01/2021)
3.	Merlin, Marine A: 1 article (01/2021)
4.	Shah, Girish M: 1 article (01/2021)
5.	Shah, Rashmi G: 1 article (01/2021)
6.	Zine-Eddine, Fayçal: 1 article (01/2021)
7.	Altini, Mattia: 1 article (01/2021)
8.	Amadori, Elena: 1 article (01/2021)
9.	Bongiovanni, Alberto: 1 article (01/2021)
10.	Cittanti, Corrado: 1 article (01/2021)

Related Diseases

1.

Neuroendocrine Tumors (Neuroendocrine Tumor)

08/08/2019 - "Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival."
04/01/2015 - "Analysis of 177Lu-DOTA-octreotate therapy-induced DNA damage in peripheral blood lymphocytes of patients with neuroendocrine tumors."
01/10/2021 - "Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of 177Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells."
01/01/2021 - "In March 2014, we reported the activity and safety of 177Lu-DOTA-octreotate peptide receptor radionuclide therapy (Lu-PRRT) at two different dosages (18.5 GBq and 27.5 GBq in 5 cycles) in patients with progressive metastatic gastrointestinal neuroendocrine tumors (GI-NETs). "
01/10/2021 - "The peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTA-octreotate (LuTate) is recommended for different types of neuroendocrine tumors (NETs) which overexpress somatostatin receptors (SSTR). "

Related Drugs and Biologics

1.	Somatostatin (Somatotropin Release-Inhibiting Factor)
2.	Peptide Receptors (Peptide Receptor)
3.	Radioisotopes (Radionuclides)
4.	Somatostatin Receptors (Somatostatin Receptor)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics